Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.38 |
| ▸ | NQO1 | P15559 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | BLM | P54132 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335457 | 0.78 | IDO1 (0.54) | HIF1AEPAS1CDC25ACDC25BIDO1 | |
| SCHEMBL9350222 | 0.73 | DNMT1 (0.56) | MAPTKDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL30222271 | 0.73 | DNMT1 (0.56) | MAPTKDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL5806124 | 0.73 | MAPT (0.49) | MAPTKDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL8993580 | 0.71 | XIAP (0.39) | MAPTKDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL30002673 | 0.71 | XIAP (0.39) | MAPTKDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL20364866 | 0.69 | PIM1 (0.59) | MAPTKDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL3331894 | 0.67 | MEN1 (0.40) | MAPTKDM4EALDH1A1CYP3A4MAPK1 | |
| SCHEMBL31634605 | 0.67 | CYP1A2 (0.44) | MAPTKDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL10578988 | 0.67 | LMNA (0.56) | MAPTKDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137175-B1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | MAZENCE INC (KR) | 2013-09-25 | — | — | EP | disclosed |
| US-8404869-B2 | Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome | MAZENCE INC. (KR) | 2013-03-26 | — | — | US | disclosed |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | YUNGJIN PHARM. CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | CYP27A1, CYP46A1, PCSK9 | MAPT 1685/4885KDM4E 3921/4885ALDH1A1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.